Writing the Future of
In Vitro Antibody Discovery Services

Accelerate the way you develop antibodies, with a best-in-class in vitro discovery platform, antibody optimization services, and more.


Get in Touch

Increase Speed to Market with Streamlined,
De-Risked Antibody Development

Our unique technology enables us to print large amounts of DNA with game-changing throughput and quality. With that as our foundation, Twist Biopharma can create unprecedented synthetic antibody libraries, accelerating the way you develop antibody candidates.

 Your Partner for End-to-End Antibody Development


Best-in-Class Antibody Discovery Platform

Twist Antibody Optimization (TAO)

Development Partnerships and Collaborations

Writing the Next Chapter in Antibody Therapeutics

Writing the Next Chapter in Antibody Therapeutics

Our DNA writing capabilities, combined with our leading bioinformatics expertise, give us the ability to offer unique benefits for lead identification and optimization. Twist’s antibody discovery platform, the “Library of Libraries,” and any custom libraries we build, are designed rationally, focused on interrogating only the desired sequence space. We can also remove frame shifts, stop codons, and potential downstream manufacturing liabilities, such as isomerization, cleavage, deamidation, glycosylation, or problematic dipeptide motifs from sequence space, empowering faster and de-risked discovery and optimization efforts.

Twist Biopharma provides end-to-end solutions
in biologic drug discovery and early development

We offer tailored services and workflows for your individual needs, across the preclinical continuum. In addition to our antibody discovery and optimization services, we offer supporting development capabilities, including IgG conversion, expression, purification, biophysical characterization, and functional characterization. And if you want to quickly tap into potent antibodies, our antibody experts have discovered and vetted a collection of antibodies against an array of high-value targets from important therapeutic areas, such as immuno-oncology, obesity and diabetes, rare metabolic diseases, and COVID-19.

Speak with an Expert

Ways You Can Work With Us

License our Libraries

Generate Custom Libraries

High-Throughput IgG Production and Characterization

Partner and Generate New Antibodies Against Your Target of Interest

Partner to Optimize Existing Antibodies with Twist Antibody Optimization

Partner or Collaborate to Develop from Initial Proof-of-Concept

Our Process

Step 1
Construct phage library or use pre-constructed library
Step 2
Cell-based or bead-based selections
Step 3
NGS & Sanger clone sequencing
Step 4
Reformatting to IgG, DNA scale-up, and expression
Step 5
High-throughput IgG purification
Step 6
Binding & functional assays

What Scientists Have to Say

Twist is the only synthetic DNA provider who can deliver the quantity and quality of DNA we need for our projects rapidly. We are working with them not only as a vendor for synthetic genes and antibodies, but have expanded our relationship to leverage the Twist Biopharma capabilities, which we believe complement our antibody discovery efforts.
Robert Carnahan, PhD
Associate Director of the Vanderbilt Vaccine Center
Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients” .,
Clive R. Wood, Ph.D
Senior Corporate Vice President and Global Head of Discovery Research Boehringer Ingelheim

Interested in partnering with us?

Get in Touch